Promoter competition for gene therapy of SCID-X1

Human Gene Therapy

Volumn 22, Issue 3, 2011, Pages 255-256

  Baum, Christopher ^a   Schambach, Axel ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2 RECEPTOR GAMMA; LENTIVIRUS VECTOR;

BONE MARROW TRANSPLANTATION; GENE EXPRESSION REGULATION; HEMATOPOIESIS; LEUKEMOGENESIS; NONHUMAN; NOTE; PROMOTER REGION; VIRAL GENE THERAPY; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

ANIMALS; GENE THERAPY; GENETIC VECTORS; HUMANS; LENTIVIRUS; PROMOTER REGIONS, GENETIC; X-LINKED COMBINED IMMUNODEFICIENCY DISEASES;

EID: 79952658028     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2011.2280     Document Type: Note

References (20)

1. Almarza, E., Rio, P., Meza, N.W., et al. (2007). Characteristics of lentiviral vectors harboring the proximal promoter of the vav proto-oncogene: A weak and efficient promoter for gene therapy. Mol. Ther. 15, 1487-1494. (Pubitemid 47099306)
2. Almarza, E., Zhang, F., Santilli, G., et al. (2011). Correction of SCID-X1 using an enhancerless Vav promoter. Hum. Gene Ther. 22, 263-270.
3. Brown, B.D., Venneri, M.A., Zingale, A., et al. (2006). Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat. Med. 12, 585-591.
4. Dave, U.P., Akagi, K., Tripathi, R., et al. (2009). Murine leuke-mias with retroviral insertions at LMO2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy. PLoS Genet. 5, e1000491.
5. Gehrke, S., Jerome, V., and Muller, R. (2003). Chimeric tran-scriptional control units for improved liver-specific transgene expression. Gene 322, 137-143. (Pubitemid 37485990)
6. Ginn, S.L., Liao, S.H., Dane, A.P., et al. (2010). Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gc overexpression. Mol. Ther. 18, 965-976.
7. Hammer, K., Mijakovic, I., and Jensen, P.R. (2006). Synthetic promoter libraries-tuning of gene expression. Trends Bio-technol. 24, 53-55. (Pubitemid 43151974)
8. Heckl, D., Wicke, D.C., Brugman, M.H., et al. (2011). Lentiviral gene transfer regenerates hematopoietic stem cells in a mouse model for Mpl-deficient aplastic anemia. Blood (in press
9. Joyner, A.L. (1991). Gene targeting and gene trap screens using embryonic stem cells: New approaches to mammalian development. Bioessays 13, 649-656. (Pubitemid 21892587)
10. Modlich, U., Navarro, S., Zychlinski, D., et al. (2009). Insertional transformation of hematopoietic cells by self-inactivating len-tiviral and gammaretroviral vectors. Mol. Ther. 17, 1919-1928.
11. phox expression and reconstitution of superoxide production in X-CGD cells. Gene Ther. 16, 111-118.
12. \+ cells: Implications for leukemogenesis in gene therapy. Leukemia 21, 754-763. (Pubitemid 46444560)
13. Schambach, A., Galla, M., Maetzig, T., et al. (2007). Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors. Mol. Ther. 15, 1167-1173. (Pubitemid 46813620)
14. Scobie, L., Hector, R.D., Grant, L., et al. (2009). A novel model of SCID-X1 reconstitution reveals predisposition to retrovirus-induced lymphoma but no evidence of gc gene oncogenicity. Mol. Ther. 17, 1031-1038.
15. Segal, E., and Widom, J. (2009). From DNA sequence to tran-scriptional behaviour: A quantitative approach. Nat. Rev. Genet. 10, 443-456.
16. Thornhill, S.I., Schambach, A., Howe, S.J., et al. (2008). Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. Mol. Ther. 16, 590-598. (Pubitemid 351315000)
17. Woods, N.B., Bottero, V., Schmidt, M., et al. (2006). Gene therapy: Therapeutic gene causing lymphoma. Nature 440, 1123.
18. Zhang, F., Thornhill, S.I., Howe, S.J., et al. (2007). Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells. Blood 110, 1448-1457. (Pubitemid 47443959)
19. Zhou, S., Mody, D., Deravin, S.S., et al. (2010). A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human t cells. Blood 116, 900-908.
20. Zufferey, R., Donello, J.E., Trono, D., and Hope, Z.J. (1999). Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by ret-roviral vectors. J. Virol. 73, 2886-2892. (Pubitemid 29135675)